WO2022225035A1 - Dérivé d'acide biliaire ayant un effet antiviral sur le virus de l'hépatite b - Google Patents
Dérivé d'acide biliaire ayant un effet antiviral sur le virus de l'hépatite b Download PDFInfo
- Publication number
- WO2022225035A1 WO2022225035A1 PCT/JP2022/018510 JP2022018510W WO2022225035A1 WO 2022225035 A1 WO2022225035 A1 WO 2022225035A1 JP 2022018510 W JP2022018510 W JP 2022018510W WO 2022225035 A1 WO2022225035 A1 WO 2022225035A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- sul
- udc
- oso
- hbv
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title claims abstract description 63
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title claims abstract description 17
- 230000000840 anti-viral effect Effects 0.000 title abstract description 3
- 208000015181 infectious disease Diseases 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 11
- 208000006454 hepatitis Diseases 0.000 claims abstract description 11
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 11
- 201000007270 liver cancer Diseases 0.000 claims abstract description 8
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- IANJIVUFAULQJH-SHUSUIPQSA-N (5r)-5-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]hexane-1-sulfonic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCCCS(O)(=O)=O)C)[C@@]2(C)CC1 IANJIVUFAULQJH-SHUSUIPQSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims 2
- 229910004727 OSO3H Inorganic materials 0.000 abstract 3
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 41
- 238000012360 testing method Methods 0.000 description 35
- 239000000243 solution Substances 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 239000000427 antigen Substances 0.000 description 21
- 210000003494 hepatocyte Anatomy 0.000 description 21
- 239000002609 medium Substances 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 108091036055 CccDNA Proteins 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- -1 pre-C) Proteins 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 208000002672 hepatitis B Diseases 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108091006611 SLC10A1 Proteins 0.000 description 4
- 102100021988 Sodium/bile acid cotransporter Human genes 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 3
- NGALQDLKWWSXMK-ULQOMZCQSA-N (3r,5s,7s,8r,9s,10s,13r,14s,17r)-17-[(2r)-5-hydroxypentan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,7-diol Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCCO)C)[C@@]2(C)CC1 NGALQDLKWWSXMK-ULQOMZCQSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 208000037262 Hepatitis delta Diseases 0.000 description 3
- 241000724709 Hepatitis delta virus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- GHCZAUBVMUEKKP-XROMFQGDSA-N glycoursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-XROMFQGDSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- JNMALBXXJSWZQY-BBBUMGABSA-N 5alpha-cyprinol Chemical compound C([C@@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCCC(CO)CO)C)[C@@]2(C)[C@@H](O)C1 JNMALBXXJSWZQY-BBBUMGABSA-N 0.000 description 2
- 206010059193 Acute hepatitis B Diseases 0.000 description 2
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- USCOGWNSMMJTRS-UHFFFAOYSA-N Cyprinol Natural products CC(CCCC(O)O)C1CCC2C1C(O)CC3C2C(O)CC4CC(O)CCC34C USCOGWNSMMJTRS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010019837 Hepatocellular injury Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- JNMALBXXJSWZQY-UHFFFAOYSA-N Latimerol Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCCC(CO)CO)C)C1(C)C(O)C2 JNMALBXXJSWZQY-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 2
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- DIPHJTHZUWDJIK-JPLAUYQNSA-N 5beta-scymnol Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CC[C@@H](O)C(CO)CO)C)[C@@]2(C)[C@@H](O)C1 DIPHJTHZUWDJIK-JPLAUYQNSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101710142246 External core antigen Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102000044437 S1 domains Human genes 0.000 description 1
- 108700036684 S1 domains Proteins 0.000 description 1
- DIPHJTHZUWDJIK-UHFFFAOYSA-N Scymnol Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)C(CO)CO)C)C1(C)C(O)C2 DIPHJTHZUWDJIK-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 101710086987 X protein Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012767 chemiluminescent enzyme immunoassay Methods 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- YLLIGHVCTUPGEH-UHFFFAOYSA-M potassium;ethanol;hydroxide Chemical compound [OH-].[K+].CCO YLLIGHVCTUPGEH-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 108010003524 sodium-bile acid cotransporter Proteins 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Definitions
- Hepatitis B is hepatitis caused by hepatitis B virus (HBV) infection. Hepatitis B includes acute hepatitis B and chronic hepatitis B. Acute hepatitis B refers to the condition in which an adult is infected with HBV for the first time and develops the disease. It refers to a condition in which high ALT levels persist for more than a month and liver damage is present.
- HBV hepatitis B virus
- HBV-infected people There are 2 billion HBV-infected people in the world, of which 257 million are persistently infected.
- the infected person When infected with HBV during childbirth or infancy, when the immune function is immature, the infected person does not show symptoms of hepatitis, and HBV continues to proliferate in hepatocytes for a long period of time. About 90% of them undergo seroconversion from HBe antigen-positive to HBe antibody-positive, become inactive carriers, and progress to persistent infection. However, in the remaining 10%, viral activity persists and progresses to chronic hepatitis B. As chronic hepatitis B progresses, hepatocytes are destroyed and replaced by fibrous tissue during regeneration, resulting in stiffening of the liver and cirrhosis. Thus, about 2% of chronic hepatitis B patients per year progress to liver cirrhosis, and there are cases where the disease progresses further to develop liver cancer.
- HBV consists of an approximately 3.2 kb circular, partially double-stranded DNA surrounded by an envelope with a diameter of approximately 42 nm. There are at least 10 genotypes from A to J.
- the double-stranded DNA contains ORFs encoding HBs antigen proteins (pre-S1, pre-S2 and S), HBc antigen proteins (including pre-C), DNA polymerase, and X protein.
- HBV is classified into at least four subtypes (adr, adw, ayr, ayw) according to amino acid mutations (d/y, r/w) of the S protein, which is a surface antigen (HBs antigen).
- SLC10A1 (NTCP; sodium taurocholate co-transport polypeptide) was reported to be a functional receptor for both HBV and HDV (hepatitis D virus), suggesting that bile acids inhibit HBV and HDV infection. It has been reported that it can be inhibited (Elife 1: e00049 (2012); J Virol 87: 7977-7991 (2014); J Virol 88: 3273-3284 (2014); JP 2017-530194).
- a novel bile acid derivative compound and a pharmaceutical composition for preventing infection with hepatitis B virus (HBV) or treating or preventing hepatitis, cirrhosis, or liver cancer caused by HBV infection are provided.
- HBV hepatitis B virus
- bile acid derivatives inhibit the binding of NTCP to the pre-S1 region on the envelope protein of HBV, thereby inhibiting the entry of HBV into hepatocytes. I found it in The present invention includes the following embodiments.
- compositions for treating or preventing cancer comprising as an active ingredient a bile acid derivative represented by the following formula I or a pharmacologically acceptable salt thereof
- a bile acid derivative represented by the following formula I or a pharmacologically acceptable salt thereof
- R 2 is H or an ⁇ -CH 3 group.
- R 3 is an ⁇ -OH group or a ⁇ -OH group.
- R 5 is a —[CH(CH 3 )] m —(CH 2 ) q —OSO 3 H group, —(CH 2 ) q —SO 3 H group, —(CH 2 ) q —OH group, —[CH (OH)] p —(CH 2 ) q —COOH group, —CONH—(CH 2 ) q —C 6 H 4 —COOH, and —CONH—CH(CH 2 OH)—COOH group; is a group that m, p are independently 0 or 1, and q is independently selected from 0, 1, 2, 3, 4, and 5; The pharmaceutical composition according to any one of [1] to [3].
- the bile acid derivative is CDC-sul:
- a remedy for hepatitis comprising the pharmaceutical composition according to any one of [1] to [5].
- a drug for treating liver cirrhosis comprising the pharmaceutical composition according to any one of [1] to [5].
- a drug for treating liver cancer comprising the pharmaceutical composition according to any one of [1] to [5].
- FIG. 3 shows the results of pre-S1 binding assay in screening bile acid derivatives in one example of the present invention.
- FIG. 1 shows the results of HBV infection inhibition test (1) using human primary hepatocytes in one example of the present invention. This figure shows the results when the medium was replaced with a liquid medium containing neither the test compound nor the pre-S1 peptide when the liquid medium was replaced on days 1, 2, 7, and 12 after infection. ing.
- FIG. 1 shows the results of HBV infection inhibition test (1) using human primary hepatocytes in one example of the present invention. This figure shows the results when the medium was replaced with a liquid medium containing the test compound at the time of liquid medium replacement on days 1, 2, 7 and 12 after infection.
- FIG. 1 shows the results of HBV infection inhibition test (1) using human primary hepatocytes in one example of the present invention. This figure shows the results when the medium was replaced with a liquid medium containing the test compound at the time of liquid medium replacement on days 1, 2, 7 and 12 after infection.
- FIG. 1 shows the results of HBV infection inhibition test (1) using human primary hepatocytes in one example of the present invention. This figure shows the results when the medium was replaced with a liquid medium containing pre-S1 peptide at the time of liquid medium replacement on days 1, 2, 7 and 12 after infection.
- FIG. 2 shows the results of HBV infection inhibition test (2) using PXB cells (primary human hepatocytes) in one example of the present invention. HomoUDC-sul has been shown to inhibit HBV infection.
- Fig. 2 shows the results of HBV infection inhibition test (2) using PXB cells (primary human hepatocytes) in an example of the present invention, showing inhibition of HBV infection by UDC-O-sul.
- FIG. 2 shows the results of HBV infection inhibition test (2) using PXB cells (primary human hepatocytes) in one example of the present invention. Inhibition of HBV infection by BishomoUDC-sul is shown.
- FIG. 2 shows the results of a pre-S1 binding assay showing that the bile acid derivative of one example of the present invention acts directly on viral pre-S1.
- FIG. 2 shows the results of a hepatoprotective effect test of a bile acid derivative against hepatocellular damage induced by taurochenodeoxycholic acid (TCDCA) using human primary hepatocytes in one example of the present invention. Lactose dehydrogenase (LDH) activity in cultures of human primary hepatocytes dosed with each test compound is shown.
- TCDCA taurochenodeoxycholic acid
- One embodiment of the present invention is a pharmaceutical composition for preventing hepatitis B virus (HBV) infection or treating hepatitis, cirrhosis, or liver cancer caused by HBV infection, containing a bile acid derivative as an active ingredient. It is a thing.
- a bile acid derivative or a pharmaceutically acceptable salt thereof has a medical effect because the bile acid derivative binds to HBV, thereby inhibiting the entry of HBV from NTCP into cells, and as a result, causing HBV to enter the liver. This is thought to be for the purpose of inhibiting cell infection.
- the bile acid derivative compound is preferably represented by Formula I below, more preferably represented by Formula II below, even more preferably represented by Formula III below, and further preferably represented by Formula IV below. is more preferred. These compounds are preferable to conventionally known compounds in that they have the effect of protecting cells from cytotoxicity.
- R 2 is —H, ⁇ -OH group, ⁇ -OH group, ⁇ -CH 3 group
- R 3 is —H, an ⁇ -OH group, a ⁇ -OH group, or a ⁇ -OSO 3 H group
- R 4 is a -H or ⁇ -OH group
- R 5 is —[CH(CH 3 )] m —(CONH) O —[CH(OH)] p —(CH 2 ) q —R 7 — ⁇ CH[(CH 2 ) n OH] ⁇ r —( CH 2 ) s —R 8 groups
- o is 0 or 1, when o is 0, R7 is a bond; when o is 1, R 7 is a bond, -C 6 H 4 -, -C 6 H 5 -, -CH(COOH)-, or -CH
- R 1 is an ⁇ -OH group or a ⁇ -OH group
- R 2 is a —H, ⁇ -CH 3 group
- R 3 is -H, an ⁇ -OH group or a ⁇ -OH group
- R 4 is a -H or ⁇ -OH group
- R 5 is a —(CONH) O —[CH(OH)] p —(CH 2 ) q —R 7 — ⁇ CH[(CH 2 ) n OH] ⁇ r —(CH 2 ) s —R 8 group
- o is 0 or 1, when o is 0, R7 is a bond; when o is 1, R 7 is -C 6 H 4 - or -CH(COOH)-;
- p, q, r, s, n are independently selected from 0, 1, 2, and 3
- R 8 is a —OSO 3 H group, —SO 3 H group, —OH group, or —COOH group
- R 6 is a
- R 1 is an ⁇ -OH group
- R 2 is H or an ⁇ -CH 3 group
- R 3 is an ⁇ -OH group or a ⁇ -OH group
- R 4 is H
- R 5 is a —[CH(CH 3 )] m —(CH 2 ) q —OSO 3 H group or —[CH(CH 3 )] m —(CH 2 ) q —SO 3 H group
- m is 0 or 1 and q is independently 0, 1, 2, 3, 4 or 5
- R 6 is ⁇ -H).
- R 1 is an ⁇ -OH group
- R 2 is H or an ⁇ -CH 3 group
- R 3 is an ⁇ -OH group or a ⁇ -OH group
- R 4 is H
- R 5 is a —(CH 2 ) q —OSO 3 H group or a —(CH 2 ) q —SO 3 H group
- q is 0, 1, 2 or 3
- R 6 is ⁇ -H
- the bile acid derivative compounds are CDC-sul, UDC-sul, BishomoCDC-sul, BishomoUDC-sul, 25-Me-bishomo-UDC-sul, Trishomo-UDC-sul, and Tetrakishomo-UDC-sul, HomoCDC-sul. , HomoUDC-sul, CDC-O-sul, UDC-O-sul, UDC-OH, UDC-PABA, UDC-ser, GUDCA and iso-UDCA are preferred.
- the compounds represented by Formula (III) and Formula (IV) are useful not only for the pharmaceutical composition of the present disclosure, but also as compounds having other uses.
- Pharmaceutically acceptable salts refer to salts of active compounds prepared with acids or bases, depending on the particular substituents present on the compounds described herein.
- Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine, or magnesium salts, or a similar salt.
- Examples of pharmaceutically acceptable acid addition salts include inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrocarbonic acid, phosphoric acid, monohydrogenphosphate, dihydrogenphosphate, sulfuric acid, Salts derived from hydrogensulfuric acid, hydroiodic acid, or phosphoric acid, etc., and organic acids such as acetic acid, propionic acid, isobutyric acid, oxalic acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, Salts derived from mandelic acid, phthalic acid, benzenesulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, methanesulfonic acid and the like.
- inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrocarbonic acid, phosphoric acid, monohydrogenphosphate,
- the pharmaceutical composition described above can be used as a preventive agent for HBV infection, a therapeutic agent for hepatitis, a therapeutic agent for liver cirrhosis, and a therapeutic agent for liver cancer.
- these agents may optionally further contain various commonly used ingredients, such as one or more pharmaceutically acceptable excipients, disintegrants, diluents, Lubricants, flavoring agents, coloring agents, sweetening agents, flavoring agents, suspending agents, wetting agents, emulsifying agents, dispersing agents, adjuvants, preservatives, buffering agents, binders, stabilizers, coating agents, etc. obtain.
- the administration route can be either systemic administration or local administration, oral route or parenteral route.
- Parenteral routes include usual intravenous administration, intraarterial administration, as well as subcutaneous, intradermal and intramuscular administration.
- the dosage form is not particularly limited, and various dosage forms, for example, for oral administration, tablets, capsules, powders, granules, pills, liquids, emulsions, suspensions, solutions, alcoholic beverages, Syrups, extracts, and elixirs can be used, and parenteral agents include injections such as subcutaneous injections, intravenous injections, intramuscular injections, and intraperitoneal injections; formulations, ointments or lotions; sublingual agents, buccal patches for buccal administration; and aerosols for nasal administration; suppositories. These formulations can be produced by known methods commonly used in formulation processes. Additionally, the dosage form may be a sustained or sustained release dosage form.
- the amount of the active ingredient contained in the drug can be appropriately determined according to the dose range of the active ingredient, the number of doses, etc.
- the dosage is not particularly limited, and the efficacy of the ingredients contained, the dosage form, the route of administration, the type of disease, the nature of the subject (weight, age, medical condition, use of other medicines, etc.), and the doctor in charge It is appropriately selected according to judgment.
- suitable doses range, for example, from about 0.01 ⁇ g to 100 mg, preferably from about 0.1 ⁇ g to 1 mg per kg body weight of the subject.
- these doses can be adjusted using routine experimentation well known in the art.
- the above doses can be administered once to several times daily or in divided doses every other day.
- the test method according to one embodiment of the present invention is to determine whether a compound according to the following formula (I) inhibits the binding of pre-S1 peptide to cells in vitro, or whether HBV binds to or infects cells. It is a method to check whether or not it hinders doing.
- a specific test method can be easily conceived by those skilled in the art from routine experimental methods, and examples thereof include the methods described in Examples.
- R 2 is —H, ⁇ -OH group, ⁇ -OH group, ⁇ -CH 3 group
- R 3 is —H, an ⁇ -OH group, a ⁇ -OH group, or a ⁇ -OSO 3 H group
- R 4 is a -H or ⁇ -OH group
- R 5 is —[CH(CH 3 )] m —(CONH) O —[CH(OH)] p —(CH 2 ) q —R 7 — ⁇ CH[(CH 2 ) n OH] ⁇ r —( CH 2 ) s —R 8 groups
- o is 0 or 1, when o is 0, R7 is a bond; when o is 1, R 7 is a bond, -C 6 H 4 -, -C 6 H 5 -, -CH(COOH)-, or -CH
- HepG2-hNTCP-C4 cells stably expressing human NTCP (Iwamoto M et al. Biochem Biophys Res Commun 2014;443:808-813) were provided by the National Institute of Infectious Diseases.
- uPA/SCID humanized chimeric mice (PXB mice) with livers composed of more than 90% human hepatocytes were purchased from PhoenixBio Co., Ltd. (Hiroshima, Japan).
- Human hepatocytes (PXB cells) from PXB mice were purchased from PhoenixBio Co., Ltd. (Hiroshima, Japan) and cultured according to the manufacturer's instructions.
- ⁇ Detection method> The amount of extracellular HBV DNA and the amount of intracellular cccDNA were quantified using real-time PCR using the LightCycler96 system (Roche Diagnostics, Mannheim, Germany). DNA in the culture supernatant and cell DNA were extracted using QIAamp DNA Blood Mini kit and QIAamp DNA Mini kit (Qiagen, Valencia, CA, USA), respectively. Primer and probe sequences used for quantification are shown below.
- HBV DNA (Fw): 5'-CTT CAT CCT GCT GCT ATG CCT-3' (SEQ ID NO: 2)
- HBV DNA (Rev): 5'-AAA GCC CAG GAT GAT GGG AT-3' (SEQ ID NO: 3)
- HBV DNA (Probe): 5'-FAM-ATG TTG CCC GTT TGT CCT CTA ATT CCA G-TAMRA-3' (SEQ ID NO: 4)
- HBVcccDNA (Fw): 5'-CGT CTG TGC CTT CTC ATC TGC-3' (SEQ ID NO: 5)
- HBVcccDNA (Rev): 5'-GCA CAG CTT GGA GGC TTG AA-3' (SEQ ID NO: 6)
- HBVcccDNA (Probe): 5'-FAM-CTG TAG GCA TAA ATT GGT-MGB-3' (SEQ ID NO: 7)
- HBs antigen and HBe antigen were quantified using HISCL HBsAg reagent (Sysmex, Kobe, Japan) and HISCL HBeAg reagent (Sysmex), respectively, using an automated chemiluminescent enzyme immunoassay system (HISCL-800; Sysmex). .
- Cytotoxicity was evaluated by quantifying lactose dehydrogenase (LDH) activity in the culture medium using a cytotoxicity detection kit (LDH) (Sigma-Aldrich, St. Louis, MO, USA).
- reaction solution was adjusted to pH 3 by adding HCl aqueous solution (2N), extracted with ethyl acetate, and washed with H 2 O and saturated sodium bicarbonate aqueous solution.
- the resulting organic layer was dehydrated with magnesium sulfate, filtered through a cotton plug, and then ethyl acetate was distilled off under reduced pressure.
- the resulting residue was purified with a silica gel column and dried under vacuum to obtain compound 7 (485 mg, yield: 64%).
- Compound 7 (485 mg, 0.864 mmol) was dissolved in acetone (30 ml) followed by sodium iodide (648 mg, 4.32 mmol) and stirred at 40° C. for 15 hours.
- Trifluoroacetic acid 50 ml was added to the obtained compound 10, trifluoroacetic anhydride (5.41 ml, 38.4 mmol) was added under an argon gas stream, and the mixture was stirred at 0°C for 1 hour. Subsequently, sodium nitrite (636 mg, 9.22 mmol) was added to the reaction solution, and the mixture was stirred at 0°C for 1 hour, warmed to 50°C, and further stirred for 1 hour. Thereafter, the reaction solution was returned to room temperature, and the desired product was precipitated in ice water to obtain compound 11. A 10% KOH solution (50% EtOH aqueous solution) was added to the obtained compound 11, and the mixture was stirred at 80°C for 15 hours.
- Homo-UDCA (12) (2.56 g, 6.33 mmol) was dissolved in THF (65 ml), and TEA (4.10 ml, 31.5 mmol) and ethyl chloroformate (3.00 ml, 31.5 mmol) were dissolved under an argon gas stream. 5 mmol) was added and stirred at 0° C. for 3 hours. After that, 10% NaBH 4 /H 2 O (5 g/50 ml) was further added and stirred at 0° C. for an hour.
- pre-S1 binding assay HepG2-hNTCP-C4 cells were treated with 40 nM TAMRA-labeled N-terminal myristoylated peptide corresponding to amino acids 2-48 of the pre-S1 domain (TAMRA-pre- S1-lipopeptide).
- the N-terminal myristoylated peptide has the following sequence.
- Myristoyl-GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANKVG SEQ ID NO: 1 After incubation for 30 minutes at 37°C, cells were washed and fixed with 4% paraformaldehyde solution.
- CDC-sul, UDC-sul, LC-sul, BishomoCDC-sul, Cyprinol sulfate, Ssymnol sulfate, 25-Me-bishomo-UDC-sul, Trishomo-UDC-sul, Tetrakishomo-UDC-sul are pre -has the activity of inhibiting the binding of the S1 peptide to cells.
- HBV infection inhibition test using PXB cells human primary hepatocytes
- PXB cells human primary hepatocytes
- the test compound (10 ⁇ M) was pretreated with the respective test compound (10 ⁇ M) for 3 hours and then infected with genotype C HBV at 5 genome equivalents/cell in the presence of 4% polyethylene glycol 8000 and the same test compound (10 ⁇ M). rice field. Twenty hours after infection, the medium was replaced with a liquid medium containing no test compound, and then on the 2nd, 7th and 12th days, the medium was replaced with a liquid medium containing no test compound. Culture supernatants were collected 17 days after infection and the concentrations of HBs antigen, HBe antigen, extracellular HBV DNA and intracellular cccDNA were measured.
- the same experiment was performed using DMSO alone or Cyclosporin A (4 ⁇ M) instead of the test compound, and the control value was set to 1 for HBs antigen, HBe antigen, extracellular HBV DNA and intracellular cccDNA. It was represented in a graph as a relative value when Furthermore, the test was performed under the same conditions except that the liquid medium was replaced with a liquid medium containing the test compound when the liquid medium was replaced on the 1st, 2nd, 7th and 12th days after infection. Antigen, extracellular HBV DNA and intracellular cccDNA were measured (Fig. 2B).
- UDC-OH, UDC-PABA, UDC-ser, GUDCA, and iso-UDCA also observed particularly strong suppression of the expression of both HBs antigen and HBe antigen.
- HomoUDC-sul, UDC-O-sul, BishomoUDC-sul, UDC-OH, UDC-PABA, UDC-ser, GUDCA, and iso-UDCA strongly inhibited HBV cell infection in human primary hepatocytes. do.
- HBV infection inhibition test using PXB cells human primary hepatocytes
- PXB cells human primary hepatocytes
- PXB cells were pretreated with serially diluted HomoUDC-sul, UDC-O-sul, or BishomoUDC-sul for 3 hours and then genotyped at 5 genome equivalents/cell in the presence of 4% polyethylene glycol 8000. infected with HBV of C. On days 1 and 2 after infection, the medium was replaced with a liquid medium containing no test compound and cultured.
- Binding test to pre-S1 peptide Cultured HepG2-hNTCP-C4 cells were used to prepare the following groups (A) to (C).
- A Group to which test compound and peptide were added at the same time 40 nM TAMRA-pre-S1-lipopeptide was added to HepG2-hNTCP-C4 cells, and in the presence of 30 ⁇ M test compound, it was incubated at 37° C. for 30 minutes. Then washed.
- B Group treated with test compound and then added with the peptide 30 ⁇ M test compound and 40 nM TAMRA-pre-S1-lipopeptide were mixed in advance, incubated at 37° C. for 30 minutes, and fractionated.
- HomoUDC-sul, UDC-O-sul, and BishomoUDC-sul have the activity of inhibiting the binding of HBV to hepatocytes by binding to pre-S1 of HBV.
- the present invention provides novel bile acid derivative compounds and pharmaceutical compositions for preventing infection with hepatitis B virus (HBV), or treating or preventing hepatitis, cirrhosis, or liver cancer caused by HBV infection. be able to.
- HBV hepatitis B virus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
Abstract
Le but de la présente invention est de fournir un dérivé d'acide biliaire ayant un effet antiviral sur le virus de l'hépatite B. L'invention concerne spécifiquement une composition pharmaceutique destinée à prévenir une infection par le virus de l'hépatite B (VHB) ou à traiter ou à prévenir une hépatite, une cirrhose du foie, ou un cancer du foie résultant d'une infection par le VHB, la composition pharmaceutique contenant, en tant que principe actif, un dérivé d'acide biliaire représenté par la formule I ou un sel pharmacologiquement acceptable de celui-ci. (I) (Ici, chaque groupe est indépendant, et R1 est un groupe α–OH, un groupe β–OH, un groupe α–OSO3H, ou =O ; R2 est –H, un groupe α–OH, un groupe β–OH, ou un groupe α–CH3 ; R3 est –H, un groupe α–OH, un groupe β–OH, ou un groupe β–OSO3H ; R4 est –H ou un groupe α–OH ; R5 est un groupe –[CH(CH3)]m–(CONH)O–[CH(OH)]p–(CH2)q–R7–{CH[(CH2)nOH]}r–(CH2)s–R8 ; o est 0 ou 1, et si o est 0, R7 est une liaison, et si o est 1, R7 est une liaison, –C6H4–, –C6H5–, –CH(COOH)–, ou –CH(CH2OH)–; m, p, q, r, s, et n sont indépendamment choisis parmi 0, 1, 2, 3, 4, et 5 ; R8 est un groupe –OSO3H, un groupe –SO3H, un groupe –OH, ou un groupe –COOH ; et R6 est α–H ou β–H.)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023515528A JPWO2022225035A1 (fr) | 2021-04-22 | 2022-04-22 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021072888 | 2021-04-22 | ||
JP2021-072888 | 2021-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022225035A1 true WO2022225035A1 (fr) | 2022-10-27 |
Family
ID=83723044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/018510 WO2022225035A1 (fr) | 2021-04-22 | 2022-04-22 | Dérivé d'acide biliaire ayant un effet antiviral sur le virus de l'hépatite b |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2022225035A1 (fr) |
WO (1) | WO2022225035A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019139126A1 (fr) * | 2018-01-11 | 2019-07-18 | 国立大学法人東京大学 | Inhibiteur de ntcp |
WO2020063632A1 (fr) * | 2018-09-25 | 2020-04-02 | Yichang Humanwell Pharmaceutical Co., Ltd | Régulateur de la signalisation tgr5 en tant qu'agent immunomodulateur |
WO2021070883A1 (fr) * | 2019-10-07 | 2021-04-15 | 国立研究開発法人理化学研究所 | Anticorps de liaison au ntcp humain pouvant inhiber l'infection par le virus de l'hépatite b (vhb) d'hépatocytes humains |
-
2022
- 2022-04-22 JP JP2023515528A patent/JPWO2022225035A1/ja active Pending
- 2022-04-22 WO PCT/JP2022/018510 patent/WO2022225035A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019139126A1 (fr) * | 2018-01-11 | 2019-07-18 | 国立大学法人東京大学 | Inhibiteur de ntcp |
WO2020063632A1 (fr) * | 2018-09-25 | 2020-04-02 | Yichang Humanwell Pharmaceutical Co., Ltd | Régulateur de la signalisation tgr5 en tant qu'agent immunomodulateur |
WO2021070883A1 (fr) * | 2019-10-07 | 2021-04-15 | 国立研究開発法人理化学研究所 | Anticorps de liaison au ntcp humain pouvant inhiber l'infection par le virus de l'hépatite b (vhb) d'hépatocytes humains |
Non-Patent Citations (5)
Title |
---|
CLAUDIO D’AMORE, FRANCESCO SAVERIO, DI LEVA, VALENTINA SEPE, BARBARA RENGA, CHIARA DEL GAUDIO, MARIA VALERIA, D ' AURIA, ANG: "Design, Synthesis, and Biological Evaluation of Potent Dual Agonists of Nuclear and Membrane Bile Acid Receptors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 57, no. 3, 13 February 2014 (2014-02-13), pages 937 - 954, XP055165457, ISSN: 00222623, DOI: 10.1021/jm401873d * |
ISHIZUKA SATOSHI: "Variation of Molecular Species of Bile Acids: Structure, Metabolism, and Physiological Influence", KAGAKU TO SEIBUTSU - CHEMISTRY AND BIOLOGY, GAKKAI SHUPPAN SENTA / JAPAN SCIENTIFIC SOCIETIES PRESS, JP, vol. 52, no. 5, 1 May 2014 (2014-05-01), JP , pages 301 - 306, XP055979040, ISSN: 0453-073X, DOI: 0.1271/kagakutoseibutsu.52.301 * |
KIHIRA KENJI, YOSHII MICHIKO, OKAMOTO AKIRA, IKAWA SEIICHIRO, ISHII HISAKO, HOSHITA TAKAHIKO, KKIHIRA -, K, YOSHII M, OKAMOTO A, : "Synthesis of new bile salt analogues, sodium 3a ,7a-di hyd roxy-5p-c holane-24-sulfonate and sodium 3a ,7p-d i hyd roxy-5p-c holane-24-su lfonate", JOURNAL OF LIPID RESEARCH, vol. 31, no. 7, 1 July 1990 (1990-07-01), pages 1323 - 1326, XP055979017, DOI: 10.1016/S0022-2275(20)42642-2 * |
MIKAMI, T. et al. 15α-Hydroxylation of a bile acid analogue, sodium 3α,7α-dihydroxy-25,26-bishomo-5β-cholane-26-sulfonate in the hamster. Journal of Lipid Research. 1996, vol. 37, pp. 1189-1197 * |
MIKI SHIGEO, ET AL: "Sulfonate analogs of chenodeoxycholic acid: metabolism of sodium 3.alpha.,7.alpha.-dihydroxy-25-homo-5.beta.-cholane-25-sulfonate and sodium 3.alpha.,7.alpha.-dihydroxy-24-nor-5.beta.-cholane-23- sulfonate in the hamster", JOURNAL OF LIPID RESEARCH, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC., US, vol. 33, no. 11, 1 November 1992 (1992-11-01), US , pages 1629 - 1637, XP002520342, ISSN: 0022-2275, DOI: 10.1016/S0022-2275(20)41385-9 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022225035A1 (fr) | 2022-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Locarnini et al. | The hepatitis B virus and common mutants | |
JP4040578B2 (ja) | C型肝炎ウイルスに対して活性な大環状ペプチド | |
JP4060801B2 (ja) | Ns3(c型肝炎)の抑制のための置換キノリンのヒドロキシプロリンエーテルを有するトリペプチド | |
Bozdayi et al. | Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from Turkish patients with chronic HBV infection | |
US6642204B2 (en) | Hepatitis C inhibitor tri-peptides | |
US20030224977A1 (en) | Macrocyclic peptides active against the hepatitis C virus | |
CA3017020A1 (fr) | Agents antiviraux contre l'hepatite b | |
US20040002448A1 (en) | Macrocyclic peptides active against the hepatitis C virus | |
US20170022150A1 (en) | Hepatitis b antiviral agents | |
EP2624837A2 (fr) | Nouveaux inhibiteurs de la sécrétion d'antigènes du virus de l'hépatite b | |
US6306899B1 (en) | Inhibition and treatment of Hepatitis B virus and Flavivirus by Helioxanthin and its analogs | |
CN106902347A (zh) | 亲环孢素抑制剂的用途 | |
CN106565785A (zh) | 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途 | |
CA2475446A1 (fr) | Variants viraux presentant une sensibilite modifiee par rapport aux analogues nucleosidiques et leurs applications | |
WO2022225035A1 (fr) | Dérivé d'acide biliaire ayant un effet antiviral sur le virus de l'hépatite b | |
CN106902346A (zh) | 药物组合物及其制药用途 | |
JPH09502453A (ja) | オキサチオランと、その製造方法と、それを含む医薬組成物 | |
AU2006230802A1 (en) | Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof | |
AU2019382521B2 (en) | Crystal form of hepatitis B surface antigen inhibitor | |
CN105461773B (zh) | 索非布韦的制备方法及其中间体 | |
WO2021188414A1 (fr) | Composés hétérocycliques fonctionnalisés utiles en tant qu'agents antiviraux | |
WO2024114709A1 (fr) | Forme cristalline d'un composé dérivé d'hétérocycle fusionné | |
Lee et al. | Recent Research and Knowledge on Treatment for Hepatitis B | |
WO2023151358A1 (fr) | Inhibiteur durable d'entrée du virus de l'hépatite | |
US20060106070A1 (en) | Novel pyridine-based metal chelators as antiviral agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22791806 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023515528 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22791806 Country of ref document: EP Kind code of ref document: A1 |